Health Affairs, 27, no. 1 (2008): 130-139
doi: 10.1377/hlthaff.27.1.130
© 2008 by Project HOPE
 
New Online
 * Getting Health Reform Done
 * After the State of the Union
 * Incremental Reform
 * E-Health in Developing World
 * Most-Read Articles in 2009
This Article
* Full Text (HTML)
* Reprint (PDF)
* Submit a response to this article
* Comments: View responses
* Alert me when this article is cited
* Alert me when Comments are posted
* Alert me if a correction is posted
Services
* E-mail this article to a friend
* Similar articles in this journal
* Similar articles in PubMed
* Alert me to new issues of the journal
* Add to My Personal Archive
* Download to Citation Manager
*Reprints & Permissions
Citing Articles
* Citing Articles via HighWire
* Citing Articles via Web of Science (5)
* Citing Articles via Google Scholar
Google Scholar
* Articles by Outterson, K.
* Articles by Kesselheim, A. S.
* Search for Related Content
PubMed
* PubMed Citation
* Articles by Outterson, K.
* Articles by Kesselheim, A. S.
Related Collections
* Access To Care
* International Issues
* Consumer Issues
* Vaccines

Drugs & Vaccines

Market-Based Licensing For HPV Vaccines In Developing Countries

Kevin Outterson and Aaron S. Kesselheim

Human papillomavirus (HPV) vaccines hold great promise for preventing cervical cancer, but 93 percent of mortality worldwide occurs in low- and middle-income countries, where high vaccine costs can restrict dissemination. Current models for promoting international access to health care innovations include differential pricing, advance market commitments, and voluntary and compulsory licensing. Some of these mechanisms have been effective, but much room for improvement remains. We discuss the usefulness of a new type of license that uses market forces to lower prices through generic competition in low- and middle-income countries while ensuring that pharmaceutical companies are appropriately reimbursed for their research and development.


Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati    What's this?


This article has been cited by other articles:


Home page
Health Aff (Millwood)Home page
T. Amin, R. Rajkumar, P. Radhakrishnan, and A. S. Kesselheim
Expert Review Of Drug Patent Applications: Improving Health In The Developing World
Health Aff., September 1, 2009; 28(5): w948 - w956.
[Abstract] [Full Text] [PDF]


Home page
J Law Med EthicsHome page
J. H. Reichman
Comment: Compulsory Licensing of Patented Pharmaceutical Inventions: Evaluating the Options
J. Law Med. Ethics, June 1, 2009; 37(2): 247 - 263.
[PDF]


Home page
NEJMHome page
A. S. Kesselheim
Drug Development for Neglected Diseases -- The Trouble with FDA Review Vouchers
N. Engl. J. Med., November 6, 2008; 359(19): 1981 - 1983.
[Full Text] [PDF]


Home page
BMJHome page
D. A Chokshi and A. S Kesselheim
Rethinking global access to vaccines
BMJ, April 5, 2008; 336(7647): 750 - 753.
[Full Text] [PDF]

Comments:

Read all Comments

Feasibility of GO (Generic Open) License
Manthan D. Janodia, et al.
Health Affairs, 16 Jan 2008 [Full text]